The Globe and Mail reports in its Thursday, Dec. 21, edition that Raymond James analyst Brian MacArthur has reaffirmed his "outperform" recommendation for Cameco. The Globe's David Leeder writes in the Eye On Equities column that Mr. MacArthur bumped his share target to $71 from $69. Analysts on average target the shares at $69.77. Mr. MacArthur says in a note: "Cameco provides investors with lower-risk exposure to the uranium market given its diversification of sources. These sources are supported by a portfolio of long-term contracts that provide some downside protection in periods of depressed spot uranium prices, while maintaining optionality to higher uranium prices. In addition, Cameco has multiple operations curtailed that could be brought back should uranium prices increase. Although the 2021 tax court decision applies only to the 2003, 2005, and 2006 tax years, we view it as a positive for Cameco given we believe it could be relevant in determining the outcome for other years and reduces risk related to the [Canada Revenue Agency] dispute." The Globe reported on Sept. 15 that Mr. MacArthur was sticking with his "outperform" call on Cameco when its shares could be had for $53.90.